Nationwide Data Center Protests Highlight Growing Backlash Against AI Expansion 
Samsung Biologics Launches $1.81 Billion Bid to Acquire PolyPeptide 
Bank of America Says These Overlooked AI Stocks Could Be the Next Winners 
Belimo H1 Sales Surge as AI Data Center Cooling Drives More Than Half of Growth 
SpaceX Aborts Starship Test Flight as Engine Issue Delays Launch 
Seven & i Eyes Żabka Stake in Major European Expansion Push 
Samsung Cuts U.S. Consumer Electronics Jobs as Headquarters Moves to Texas 
KKR, AEW Seek China Property Sales as Commercial Real Estate Slump Deepens 
Ryanair Warns Summer Airfares May Stay Lower as Quarterly Profit Misses Estimates 
KPMG Australia Appoints John Sams as CEO Following Audit Leak Scandal 
Volvo Cars Q2 Profit Falls as Automaker Bets on EX60 EV to Drive Recovery 
DeepSeek Eyes $74 Billion Valuation Ahead of Planned China IPO 
Mikron H1 2026 Sales Fall 5.9% as Automation Weakness Weighs on Profit 
SpaceX Eyes Pentagon AI Deal as Cloud Pricing Strategy Pressures CoreWeave 
Foxconn Wins First SpaceX AI Server Contract Worth Estimated $52 Billion 
Chalco Shares Jump as Chinalco Plans Up to $300 Million Stake Increase 
Roche Holding AG agreed to buy Telavant Holdings for $7.1 billion. The Swiss healthcare firm that operates pharmaceuticals and diagnostics businesses worldwide announced on Monday, Oct. 23, that it will acquire the developer of a new treatment for inflammatory bowel diseases that Roivant Sciences and Pfizer Inc. own with a minority stake.
According to Reuters, Roche Holding will have the right to develop, produce, and commercially market Roivant Sciences and Pfizer's experimental antibody called the RVT-3101 under the terms. Roche is aiming to release this drug in the United States and Japan.
RVT-3101 in Phase 3 Trial
Roche reportedly said the RVT-3101 is a "promising" new therapy currently being developed to help patients suffering from inflammatory bowel disease, ulcerative colitis, and Crohn's disease. This bowel disease is part of a chronic gastrointestinal disorder group that affects about eight million people worldwide.
It was added that 80% of the patients are not experiencing lasting remission. Roche believes that the new RVT-3101 or TL1A antibody has a big potential to help treat other diseases. The pharma company said the drug is already close to phase 3 of the trial.
"Promising" New Treatment
"We strongly believe this novel TL1A directed antibody has the transformational potential to make a significant difference for patients living with inflammatory bowel disease and potentially other diseases," Roche Group's chief executive officer, Thomas Schinecker, said in a press release. "We are excited to add this promising new therapy in development to our portfolio and to make it available to patients as quickly as possible."
Roche's chief medical officer, who also serves as the company's head of global product development, further said, "The recent Phase 2b for RVT-3101 delivered the first long-term, robust dataset demonstrating improved clinical remission in the maintenance treatment phase and with this promising data, we believe that RVT-3101 has the potential to be the first therapy that offers both high efficacy and safety for people with inflammatory bowel disease and the convenience of an at-home, subcutaneous administration."
Photo by: Roche Media Library
